nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.06.2013 | Review article

The German evidence-based guidelines for Hodgkin’s lymphoma

Aspects for radiation oncologists

verfasst von: Prof. Dr. H.T. Eich, J. Kriz, H. Schmidberger, B. Böll, B. Klimm, M. Rancea, R.-P. Müller, A. Engert

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

This report reviews aspects of the German evidence-based guidelines for Hodgkin’s lymphoma relevant to radiation oncologists. Stage-adapted treatment is discussed with the focus on radiotherapy. Up-to-date literature citations provide an overview of current recommendations.

Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495–3502PubMedCrossRef

Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927PubMedCrossRef

Noordijk EM, Carde P, Dupouy N et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135PubMedCrossRef

Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652PubMedCrossRef

Gordon L, Hong F, Fisher R et al (2010) A randomized phase III trial of ABVD vs. Stanford V/+ radiation therapy in locally extensive and advanced stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496) (abstr 6). Blood 116

Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608PubMedCrossRef

Wit M de, Bohuslavizki KH, Buchert R et al (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12:29–37PubMedCrossRef

Weihrauch MR, Re D, Scheidhauer K et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934PubMedCrossRef

Spaepen K, Stroobants S, Dupont P et al (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272–278PubMedCrossRef

10.

Naumann R, Vaic A, Beuthien-Baumann B et al (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 115:793–800PubMedCrossRef

11.

Sher DJ, Mauch PM, Van Den Abbeele A et al (2009) Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol 20:1848–1853PubMedCrossRef

12.

Von Tresckow B, Pluetschow A, Fuchs M et al (2012) Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Final analysis of the GHSG HD14 Trial. J Clin Oncol 30(9):907–913CrossRef

13.

Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206PubMedCrossRef

14.

Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752PubMedCrossRef

15.

Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59PubMedCrossRef

16.

Hutchings M, Mikhaeel NG, Fields PA et al (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160–1168PubMedCrossRef

17.

Terasawa T, Lau J, Bardet S et al (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009 27:1906–1914CrossRef

18.

Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410PubMedCrossRef

19.

Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210PubMedCrossRef

20.

Girinsky T, Maazen R van der, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277PubMedCrossRef

21.

Engert A, Haverkamp H, Kobe C et al (2012) Reduced Intensity of Chemotherapy and PET-giuded Radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791–1799PubMedCrossRef

22.

Aleman BM, Raemaekers JM, Tirelli U et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–2406PubMedCrossRef

23.

Aleman BM, Raemaekers JM, Tomisic R et al (2007) Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 67:19–30PubMedCrossRef

24.

Loeffler M, Brosteanu O, Hasenclever D et al (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16:818–829PubMed

25.

Borchmann P, Haverkamp H, Diehl V et al (n d) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol

26.

Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994PubMedCrossRef

27.

Nogova L, Reineke T, Eich HT et al (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683–1687PubMedCrossRef

28.

Nogova L, Reineke T, Brillant C et al (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434–439PubMedCrossRef

Titel: The German evidence-based guidelines for Hodgkin’s lymphoma
Aspects for radiation oncologists
verfasst von: Prof. Dr. H.T. Eich
J. Kriz
H. Schmidberger
B. Böll
B. Klimm
M. Rancea
R.-P. Müller
A. Engert
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 6/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0331-4

Springer Medizin

The German evidence-based guidelines for Hodgkin’s lymphoma

Aspects for radiation oncologists

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients

Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy

Simultane Radiochemotherapie mit 5-FU/Mitomycin bleibt bei Behandlung von Analkanalkarzinomen der bevorzugte Standard

Mitteilungen der Fachgesellschaften

Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas

Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie